Referencias
1.Bergendal A, Adami J, Bahmanyar S, Hedenmalm K, Lärfars G, Persson I, Sundström A, Kieler H. Non-steroidal anti-inflammatory drugs and venous thromboembolism in women. Pharmacoepidemiol Drug Saf. 2013 Jun;22(6):658-66.
2.Bitzer J, Amy JJ, Beerthuizen R, Birkhäuser M, Bombas T, Creinin M, Darney PD, Vicente LF, Gemzell-Danielsson K, Imthurn B, Jensen JT, Kaunitz AM, Kubba A, Lech MM, Mansour D, Merki G, Rabe T, Sedlecki K, Serfaty D, Seydoux J, Shulman LP, Sitruk-Ware R, Skouby SO, Szarewski A, Trussell J, Westhoff C. Statement on combined hormonal contraceptives containing third- or fourth-generation progestogens or cyproterone acetate, and the associated risk of thromboembolism. J Fam Plann Reprod Health Care. 2013 Jul;39(3):156-9.
3.Blanco-Molina A, Monreal M.Venous thromboembolism in women taking hormonal contraceptives. Expert Rev Cardiovasc Ther. 2010 Feb;8(2):211-5. Review.
4.Blanco-Molina Á.Oral contraception in women with mild thrombophilia: what have we learned recently? Thromb Res. 2012 Oct;130 Suppl 1:S16-8. Review.
5.Blanco-Molina MA, Lozano M, Cano A, Cristobal I, Pallardo LP, Lete I.Progestin-only contraception and venous thromboembolism. Thromb Res. 2012 May;129(5):e257-62. Review.
6.Bonnema RA, McNamara MC, Spencer AL.Contraception choices in women with underlying medical conditions. Am Fam Physician. 2010 Sep 15;82(6):621-8. Free Article
7.Bousser MG, Crassard I.Cerebral venous thrombosis, pregnancy and oral contraceptives. Thromb Res. 2012 Oct;130 Suppl 1:S19-22. Review.
8.Centers for Disease Control and Prevention (CDC). Update to CDC's U.S. Medical Eligibility Criteria for Contraceptive Use, 2010: revised recommendations for the use of contraceptive methods during the postpartum period. MMWR Morb Mortal Wkly Rep. 2011 Jul 8;60(26):878-83. Free Article
9.Chroustova D, Kubinyi J, Jansa P, Veprekova L, Trnka J. V/P scan in diagnosis and follow-up of pulmonary embolism in 15-25-year-old females in relation to hormonal contraception use. Nucl Med Rev Cent East Eur. 2011;14(2):63-7. Free Article
10.Cochrane RA, Gebbie AE, Loudon JC. Contraception in obese older women. Maturitas. 2012 Mar;71(3):240-7. Review.
11.Culwell KR, Curtis KM.Contraception for women with systemic lupus erythematosus. J Fam Plann Reprod Health Care. 2013 Jan;39(1):9-11. Review.
12.Edelman AB, Jensen JT. Obesity and hormonal contraception: safety and efficacy. Semin Reprod Med. 2012 Dec;30(6):479-85. Review.
13.ESHRE Capri Workshop Group. Venous thromboembolism in women: a specific reproductive health risk. Hum Reprod Update. 2013 Sep-Oct;19(5):471-82.
14.Franchi F, Biguzzi E, Martinelli I, Bucciarelli P, Palmucci C, D'Agostino S, Peyvandi F. Normal reference ranges of antithrombin, protein C and protein S: effect of sex, age and hormonal status. Thromb Res. 2013 Aug;132(2):e152-7.
15.Gourdy P, Bachelot A, Catteau-Jonard S, Chabbert-Buffet N, Christin-Maître S, Conard J, Fredenrich A, Gompel A, Lamiche-Lorenzini F, Moreau C, Plu-Bureau G, Vambergue A, Vergès B, Kerlan V. Hormonal contraception in women at risk of vascular and metabolic disorders: guidelines of the French Society of Endocrinology. Ann Endocrinol (Paris). 2012 Nov;73(5):469-87.
16.Grimes DA, Stuart GS, Levi EE.Screening women for oral contraception: can family history identify inherited thrombophilias? Obstet Gynecol. 2012 Oct;120(4):889-95. Review.
17.Gurney EP, Murthy AS. Obesity and contraception: metabolic changes, risk of thromboembolism, use of emergency contraceptives, and role of bariatric surgery. Minerva Ginecol. 2013 Jun;65(3):279-88. Review.
18.Hannaford PC. Epidemiology of the contraceptive pill and venous thromboembolism. Thromb Res. 2011 Feb;127 Suppl 3:S30-4. doi: 10.1016/S0049-3848(11)70009-3. Review.
19.Jacobsen AF, Sandset PM. Venous thromboembolism associated with pregnancy and hormonal therapy. Best Pract Res Clin Haematol. 2012 Sep;25(3):319-32 Review.
20.Jick SS, Hagberg KW, Hernandez RK, Kaye JA.Postmarketing study of ORTHO EVRA and levonorgestrel oral contraceptives containing hormonal contraceptives with 30 mcg of ethinyl estradiol in relation to nonfatal venous thromboembolism. Contraception. 2010 Jan;81(1):16-21.
21.Julen O, Dubuisson JB, Lourenço AG. [Which contraception for women with increased risk of venous thromboembolism?]. Rev Med Suisse. 2011 Feb 9;7(281):351-4, 356. French.
22.Liao PV, Dollin J. Half a century of the oral contraceptive pill: historical review and view to the future. Can Fam Physician. 2012 Dec;58(12):e757-60. Free PMC Article
23.Lidegaard Ø, Milsom I, Geirsson RT, Skjeldestad FE. Hormonal contraception and venous thromboembolism. Acta Obstet Gynecol Scand. 2012 Jul;91(7):769-78. Review.
24.Lidegaard Ø, Nielsen LH, Skovlund CW, Skjeldestad FE, Løkkegaard E. Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9. BMJ. 2011 Oct 25;343:d6423. Free PMC Article
25.Lidegaard O. Critique of a Danish cohort study on hormonal contraception and VTE. J Fam Plann Reprod Health Care. 2010 Apr;36(2):103-4; author reply 104-5. Article
26.Lidegaard Ø. Hormonal contraception and venous thromboembolic risk in midlife women. Maturitas. 2013 Jan;74(1):1-2.
27.Mantha S, Karp R, Raghavan V, Terrin N, Bauer KA, Zwicker JI. Assessing the risk of venous thromboembolic events in women taking progestin-only contraception: a meta-analysis. BMJ. 2012 Aug 7;345:e4944. Review. Free PMC Article
28.Mantha S, Karp R, Raghavan V, Terrin N, Bauer KA, Zwicker JI.Assessing the risk of venous thromboembolic events in women taking progestin-only contraception: a meta-analysis. BMJ. 2012 Aug 7;345:e4944. Review.Free PMC Article
29.Milsom I, von Sydow H, Thörn AB, Björkelund C, Odlind V. [Diffuse symptoms in young women may indicate venous thromboembolism. Important to ask about the use of combined hormonal contraception]. Lakartidningen. 2012 Sep 19-26;109(38):1680-2. Swedish.
30.O'Brien SH. Contraception-Related Venous Thromboembolism in Adolescents. Semin Thromb Hemost. 2013 Dec 19. [Epub ahead of print]
31.Pillai P, Bonny AE, O'Brien SH. Contraception-related venous thromboembolism in a pediatric institution. J Pediatr Adolesc Gynecol. 2013 Jun;26(3):186-8.
32.Plu-Bureau G, Maitrot-Mantelet L, Hugon-Rodin J, Canonico M. Hormonal contraceptives and venous thromboembolism: an epidemiological update. Best Pract Res Clin Endocrinol Metab. 2013 Feb;27(1):25-34. Review.
33.Quijada Manuitt MA, Pedrós C, Quintana B, Arnau JM. [Hormonal contraception and venous thromboembolism.] Med Clin (Barc). 2013 Jun 19. pii: S0025-7753(13)00298-4. doi: 10.1016/j.medcli.2013.04.015. [Epub ahead of print] Spanish.
34.Reid R, Leyland N, Wolfman W, Allaire C, Awadalla A, Best C, Dunn S, Lemyre M, Marcoux V, Menard C, Potestio F, Rittenberg D, Singh S, Senikas V; Society of Obstetricians and Gynaecologists of Canada. SOGC clinical practice guidelines: Oral contraceptives and the risk of venous thromboembolism: an update: no. 252, December 2010. Int J Gynaecol Obstet. 2011 Mar;112(3):252-6.
35.Reid R; Society of Obstetricians and Gynaecologists of Canada.SOGC clinical practice guideline. No. 252, December 2010. Oral contraceptives and the risk of venous thromboembolism: an update. J Obstet Gynaecol Can. 2010 Dec;32(12):1192-204. English, French.
36.Rossi E, Ciminello A, Za T, Betti S, Leone G, De Stefano V. In families with inherited thrombophilia the risk of venous thromboembolism is dependent on the clinical phenotype of the proband. Thromb Haemost. 2011 Oct;106(4):646-54.
37.Rott H. Hormonal contraception in thrombophilic adolescents: risk of thrombosis and recommendations. Hamostaseologie. 2012;32(1):15-21.
38.Rott H. Thrombotic risks of oral contraceptives. Curr Opin Obstet Gynecol. 2012 Aug;24(4):235-40. Review
39.Santosa F, Moysidis T, Moerchel C, Kröger K, Bufe A. Pulmonary embolism in young people. Trends in Germany from 2005 to 2011. Hamostaseologie. 2013 Oct 31;34(1).
40.Shulman LP. The state of hormonal contraception today: benefits and risks of hormonal contraceptives: combined estrogen and progestin contraceptives. Am J Obstet Gynecol. 2011 Oct;205(4 Suppl):S9-13. Review.
41.Sidney S, Cheetham TC, Connell FA, Ouellet-Hellstrom R, Graham DJ, Davis D, Sorel M, Quesenberry CP Jr, Cooper WO. Recent combined hormonal contraceptives (CHCs) and the risk of thromboembolism and other cardiovascular events in new users. Contraception. 2013 Jan;87(1):93-100.
42.Tchaikovski SN, Rosing J.Mechanisms of estrogen-induced venous thromboembolism. Thromb Res. 2010 Jul;126(1):5-11. Review.
43.Trenor CC 3rd, Chung RJ, Michelson AD, Neufeld EJ, Gordon CM, Laufer MR, Emans SJ. Hormonal contraception and thrombotic risk: a multidisciplinary approach. Pediatrics. 2011 Feb;127(2):347-57. Review. Free PMC Article
44.Verhaeghe J. Clinical practice: Contraception in adolescents. Eur J Pediatr. 2012 Jun;171(6):895-9. Review.
45.Xu H, Eisenberg DL, Madden T, Secura GM, Peipert JF. Medical contraindications in women seeking combined hormonal contraception. Am J Obstet Gynecol. 2013 Nov 16. pii: S0002-9378(13)02035-8. doi: 10.1016/j.ajog.2013.11.023. [Epub ahead of print]
46.Zapata LB, Paulen ME, Cansino C, Marchbanks PA, Curtis KM. Contraceptive use among women with inflammatory bowel disease: A systematic review. Contraception. 2010 Jul;82(1):72-85.
47.Ziller M, Ziller V, Haas G, Rex J, Kostev K. Risk of venous thrombosis in users of hormonal contraceptives in German gynaecological practices: a patient database analysis. Arch Gynecol Obstet. 2013 Aug 4. [Epub ahead of print]
48.Pomp ER, Rosendaal FR, Doggen CJ. Smoking increases the risk of venous thrombosis and acts synergistically with oral contraceptive use. Am J Hematol. 2008 Feb;83(2):97-102.
49.Meltzer ME, Lisman T, Doggen CJ, de Groot PG, Rosendaal FR. Synergistic effects of hypofibrinolysis and genetic and acquired risk factors on the risk of a first venous thrombosis. PLoS Med. 2008 May 6;5(5):e97.
50.Pomp ER, le Cessie S, Rosendaal FR, Doggen CJ. Risk of venous thrombosis: obesity and its joint effect with oral contraceptive use and prothrombotic mutations. Br J Haematol. 2007 Oct;139(2):289-96.
51.Pomp ER, Rosendaal FR, Doggen CJ. Alcohol consumption is associated with a decreased risk of venous thrombosis. Thromb Haemost. 2008 Jan;99(1):59-63.
52.Severinsen MT, Overvad K, Johnsen SP, Dethlefsen C, Madsen PH, Tjønneland A, Kristensen SR. Genetic susceptibility, smoking, obesity and risk of venous thromboembolism. Br J Haematol. 2010 Apr;149(2):273-9.
53.Severinsen MT, Kristensen SR, Johnsen SP, Dethlefsen C, Tjønneland A, Overvad K. Smoking and venous thromboembolism: a Danish follow-up study. J Thromb Haemost. 2009 Aug;7(8):1297-303.
54.Gaborit FS, Overvad K, Nørgaard M, Kristensen SR, Tjønneland A, Severinsen MT. Alcohol intake and risk of venous thromboembolism. A Danish follow-up study. Thromb Haemost. 2013 Jul;110(1):39-45.
55.Dinger J, Möhner S, Heinemann K. Cardiovascular risk associated with the use of an etonogestrel-containing vaginal ring. Obstet Gynecol. 2013 Oct;122(4):800-8.
56.Donoso S E, Carvajal C JA. [The change in the epidemiological profile of maternal mortality in Chile will hinder the fulfillment of the Millennium 5th goal]. Rev Med Chil. 2012 Oct;140(10):1253-62.
57.Hannaford PC, Iversen L, Macfarlane TV, Elliott AM, Angus V, Lee AJ. Mortality among contraceptive pill users: cohort evidence from Royal College of General Practitioners' Oral Contraception Study. BMJ. 2010 Mar 11;340:c927.
SBG
